Kyle Hinton.
Topics covered: Pharma, biotech, FDA, gene therapy, clinical trials, drug pricing and much more.Discover announcements from companies in your industry. A few months ago, Endocyte was shedding R&D programs and staff, with questions being raised about its future. Complements the robust Advanced Accelerator Applications radioligand therapy pipeline Basel, December 21, 2018 - Novartis today announced that it has completed the acquisition of Endocyte, Inc., a US-based biopharmaceutical company focused on developing radioligand and CAR-T therapies for cancer treatment. Senior Director at Advanced Accelerator Applications, a Novartis Company Lafayette, Indiana Area 500+ connections. The aim is to selectively target tumor cells expressing a certain surface protein, using the ligand to hone in on the cancer and the radioactive atom to destroy it.
Strong performance from the pharma's drug units helped offset a 4% drop in sales from Novartis' Sandoz division, which has been battered by pricing pressures in the U.S. generic drug market. Want to share a company announcement with your peers?
Mike decided to join Endocyte, Inc. in March 2008 to work on their small molecule drug conjugates. In fact, our companion imaging agents currently in development carry radioisotopes.”Details of the pivotal trial for Lu-PSMA-617 still have to be worked out in consultation with the FDA, but it is anticipated that it will involve PSMA-positive mCRPC patients who have been treated with one antiandrogen and at least one taxane drug.As for funding the program, Sherman says Endocyte is solid. During this time, interviews will continue as planned and, where appropriate, will be switched to virtual interviews using readily available technology.
Advanced Accelerator Applications | 19,493 volgers op LinkedIn | AAA is A Novartis Company and we are focused on transforming patients’ lives by leading innovation in nuclear medicine. Advanced Accelerator Applications (AAA), a Novartis company, is an innovative company focused on the development of products for targeted radioligand therapy and precision radioligand imaging.AAA offers professionals the opportunity to face new challenges and pursue a career in a fast growing, technology-driven healthcare company.Search for career opportunities at AAA at: AAA and Novartis are monitoring the Coronavirus situation with the safety of candidates, associates and patients as our primary concern.
Novartis believes Endocyte will pair well with existing radiopharmaceutical research brought on board last year through a $3.7 billion buy of Advanced Accelerator Applications. Located in Purdue Research Park, the plant will manufacture radioligand therapies, a … Given the activity we see with Lu-PMSA-617 and the fact that this is a targeted agent for PSMA-positive patients only, we believe this will be a relatively short and targeted trial and we can fund all scenarios.”The biotech is also excited about the prospects for its CAR-T immuno-oncology program in solid tumors, and says it plans to start trials of its first candidate in pediatric osteosarcoma in collaboration with the Seattle Children’s Research Institute in the second half of 2018.Merck was purposely cautious during the start of the pandemic when it came to vaccine development but is now slowly but surely ramping up its effortsThe money will equip AlloVir to embark on a broad clinical development program for a phase 3-ready cell therapy that targets five viruses.The action keeps Bristol Myers in with a shot of winning approval before a deadline set in its takeover of Celgene. If you are currently interviewing with a Novartis Group company and have questions or concerns about your upcoming onsite interviews, please connect with your Talent Acquisition or People & Organisation (P&O) contact.We are passionate about improving patient health by leading innovation in nuclear medicine.
Now, it says its prospects have been resurrected by licensing a phase 3-ready prostate cancer drug.Mike Sherman, Endocyte’s president and CEO, says the The new licensing deal focuses on Lu-PSMA-617, a drug that in a departure from Endocyte’s earlier therapeutic focus is designed to deliver a radioisotope rather than a cell-killing chemotherapy payload.
Kyle Hinton Creative Leader. When Novartis shelled out $3.9 billion for France-based Advanced Accelerator Applications in 2017, it had blockbuster hopes for AAA’s Lutathera, a radiotherapy to treat neuroendocrine tumors (NETs).